A meta-analysis of RE-DUAL PCI, PIONEER AF-PCI and AUGUSTUS compared NOAC- and VKA-based regimens and antithrombotic therapies with and without aspirin for ischemic outcomes and CV and total mortality.
In data of the Look AHEAD trial, the effects on CV risk factors of maintaining weight loss were compared with those of weight regain, in year 1 to 4 after a 1-year intensive lifestyle intervention.
Data of the Framingham Original and Offspring Cohorts show that parental smoking during childhood is associated with a higher AF risk, partly because offspring show higher propensity of smoking.
ESC 2019 Prof. Cecilia Linde emphasizes known aspects of CVD in women, talks about the role of gender of the physician in outcomes of female patients and about the need for research of CVD in women.
Data of the BIOSTAT-CHF cohort suggest that the etiology of ID in worsening HF is multifactorial and may involve a combination of reduced iron uptake, impaired iron storage and iron loss.
A meta-analysis of 15 studies with more than 220,000 individuals showed that a mindset of optimism was associated with reduced risk of CV events and all-cause mortality.
CSI Paris Britt Heideman asks prof. Nordestgaard to explain the concept of mendelian randomization, what the advantages are, and how it compares to other research methods.
American participants of CME activities can now apply for conversion of European Board for Accreditation in Cardiology (EBAC) CME points to American Medical Association (AMA) credits.
CSI Paris Helena Oestergaard interviews George Thanassoulis on his research on identifying young individuals who would benefit of LCL-c lowering based on their lifetime CV risk.
ESC 2019 Prof. Verma gives a brief overview on SGLT2i, including data of the DAPA-HF study, potential underlying mechanisms of beneficial CV effects, and recommendations in the 2019 ESC/EASD guidelines on diabetes, pre-diabetes and CVD.
ESC 2019 Prof. Botker gives a brief summary of the CONDI-2/ERIC-PPCI trial, which evaluated whether remote ischemic remodeling results in improved outcomes in STEMI patients undergoing PCI.
Prof. Sattar shows that CV risk is heterogenous in patients with diabetes, and explains why new diabetes drugs, such as GLP-1RAs, are recommended for patients with diabetes and CV risk.